Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Suh M, Cheon G, Lee D,
Keywords: PRRT, clinical trial, Neuroendocrine tumor, Lu-177-DOTATATE,
Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Pubul V, García-Cañamaque L, Aller J,
Keywords: Lu-177-DOTATATE, radionuclide, survival, treatment,
#1419 Long Term Renal and Haematological Side Effects in NET patients Treated with Lu-177-DOTATATE
Introduction: Long term renal and bone marrow side effects may be a problem after PRRT.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Oturai P